IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ramnarayan *et al.*
Serial No.: 09/709,905
Customer No: 24961
Confirmation No.: 3606
Filed: November 10, 2000

For: *USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARAMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS*

Art Unit: 1631
Examiner: Brusca, J.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label No.: EV 338075749 US
Date of Deposit: June 3, 2003

I hereby certify that this paper and the attached papers are being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and addressed to:

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Jonathan Ong

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application, the filing fee of $180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (2 page) are provided herewith.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. and International applications which are commonly owned and/or have one or more inventors in common.

U.S.S.N.(App. No.)	Filing Date	Docket No.
10/271,181	10/10/02	1906D
10/084,794	02/25/02	19010
10/138,068	05/01/02	1912
10/394,328	03/19/03	1918

International App. No.	Filing Date	Docket No.
PCT/USO2/14138	05/01/01	1912PC
PCT/IS03/08959	03/19/03	1918PC

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
Heller Ehrman White & McAuliffe LLP

By:_____
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24737-1906C
Address all correspondence to:
Heller Ehrman White & McAuliffe LLP
Stephanie Seidman
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL sseidman@HEWM.com

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
APPLICANT Ramnarayan *et al.*	
FILING DATE November 10, 2000	GROUP 1631

*** If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	AA	5	7	3	6	5	0	9	04/07/98	Balaji *et al.*	514	9	11/10/94
	AB	6	1	2	5	2	3	5	09/26/00	Padilla *et al.*	395	500.32	06/10/97
	AC	6	2	4	2	1	9	0	06/05/01	Freire *et al.*	435	436	12/01/99

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No
None														

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AD	Abagyan *et al.*, "*Ab Initio* Folding of Peptides by the Optimal-Bias Monte Carlo Minimization Procedure", *J. Comp. Phys.*, 151:402-421, 1999
	AE	Blaney, Frank, "Molecular Modelling in the Pharmaceutical Industry", *Chemistry & Industry*, pp. 791-794, 1990
	AF	Böhm, Gerald, "New approaches in molecular structure prediction", *Biophysical Chemistry*, 59:1-32, 1996
*	AG	de Dios *et al.*, "Secondary and Tertiary Structural Effects on Protein NMR Chemical Shifts: An ab Initio Approach", *Science*, 260:1491-1496, 1993
	AH	Dudek *et al.*, "Protein Structure Prediction Using a Combination of Sequence Homology and Global Energy Minimization: II. Energy Functions", *J. Comp. Sci.*, 19:548-573, 1998
*	AI	Eisenhaber *et al.*, "Protein Structure Prediction: Recognition of Primary, Secondary, and Tertiary Structural Features from Amino Acid Sequence", *Crit. Rev. Biochem. Mol. Biol.*, 30:1-94, 1995

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan *et al.*	
	FILING DATE November 10, 2000	GROUP 1631

*** If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).**

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	AJ	Dunbrack *et al.*, "Meeting review: the Second Meeting on the Critical Assessment of Techniques for Protein Structure Prediction (CASP2), Asilomar, California, Dec. 13-16, 1996", *Folding and Design*, 1:R27-R42, 1997
*	AK	Jones, David T., "Successful Ab Initio Prediction of the Tertiary Structure of NK-Lysin Using Multiple Sequences and Recognized Supersecondary Structural Motifs", *Proteins: Structure, Function, and Genetics*, Supp. 1:185-191, 1997
	AL	Leheny *et al.*, "Symposium on Resistance Highlights New Trends in AIDS Treatments: Implications for BioChem Pharma and Others", Hambrecht & Quist LLC Institutional Research, July 21, 1997, pp. 1-7
*	AM	Osguthorpe, D.J., "Improved Ab Initio Predictions with a Simplified, Flexible Geometry Model", *Proteins: Structure, Function, and Genetics*, Suppl. 3:186-193, 1999
*	AN	Samudrala *et al.*, "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach", *Proteins: Structure, Function, and Genetics*, Supp. 3:194-198, 1999
	AO	Shenderovich *et al.*, "Structural Pharmacogenic Approach to the Evaluation of Drug Resistant Mutations in HIV-1 Protease", *J. Clinical Ligand Assay*, 24(2):140-144, 2001
	AP	Wang *et al.*, "Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance", *PNAS*, 98(26):14937-14942, 2001
	AQ	Weng *et al.*, "Prediction of protein complexes using empirical free energy functions", *Protein Science*, 5:614-626, 1996
*	AR	Westhead *et al.*, "Protein structure prediction", *Curr. Opin. Biotechnol.*, 9:383-389, 1998

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**